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Abstract In neuroblastoma X glioma hybrid, NGlOS-15, cells 
transfected to stably express a constitutively active mutant 
(CAM) form of the human Pt-adrenoceptor, the kadrenoceptor 
ligands sotalol and betaxolol functioned as inverse agonists as 
they reduced basal adenylyl cyclase activity whereas the 
antagonists dihydroalprenolol and propranolol did not. Main- 
tained presence of the CAM Pz-adrenoceptor inverse agonists but 
not the antagonists in the culture medium of the cells resulted in a 
substantial, concentration-dependent, up-regulation of the 
CAMPz-adrenoceptor. Up-regulation of the CAMP*-adrenocep- 
tor by the inverse agonists was prevented by co-incubation of the 
cells with either propranolol or dihydroalprenolol. Neither 
maintained elevation of CAMP levels nor the inhibition of 
adenylyl cyclase activity altered the ability of the inverse agonist 
ligands to cause receptor up-regulation. 
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1. Introduction 
Inverse agonists are ligands which, by binding to a receptor, 
have the capacity to modulate the basal activity of a cell 
signalling cascade in the opposite direction to that produced 
by an agonist [l-3]. Although it was applied originally to 
agents functioning, probably as negative allosteric modula- 
tors, at the GABA* receptor [4], the term has recently gained 
acceptance in the field of G protein-mediated signalling. Con- 
ceptually, agonist ligands are envisaged to stimulate signalling 
cascades by binding with higher affinity, and thus preferen- 
tially stabilising, an active conformation of a G protein- 
coupled receptor (GPCR) resulting in more effective activa- 
tion of the relevant G protein [l-3]. As a corollary, inverse 
agonists should interact preferentially with an inactive confor- 
mation of the GPCR and thus limit G protein activation [l- 
31. Such modulation implies that active and inactive confor- 
mations of a GPCR must have the thermodynamic capacity 
to interconvert spontaneously, a situation which has required 
extension and re-analysis of the ternary complex model [5,6]. 
As such, basal activity of a GPCR-regulated signalling cas- 
cade is defined by the position of the equilibrium between 
these conformations [ 11. 
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Certain mutations in GPCRs, both found naturally in the 
human population and produced artificially by site-directed 
mutagenesis, act in a manner consistent with them functioning 
as stabilised, partially active, conformations in the absence of 
agonist ligands [7]. These are termed constitutively active 
(CAM) mutations [7]. As they produce greater regulation of 
the signalling pathway in the absence of ligands than the wild- 
type forms of the same receptor then, theoretically, they may 
be very useful in the development of systems suitable for the 
easy detection and analysis of inverse agonist ligands. In the 
current study we use a CAM mutant of the human Pz-adre- 
noceptor [5] to show: (i) that sustained treatment of cells 
expressing this receptor with the inverse agonists sotalol and 
betaxolol results in up-regulation of the receptor; (ii) that 
neutral antagonists do not produce a similar effect; (iii) that 
the effect of the inverse agonists is prevented by co-incubation 
with the antagonist ligands; and (iv) that this effect is neither 
prevented by sustained elevation of cellular CAMP levels nor 
mimicked by inhibition of CAMP production. 
2. Materials and methods 
2.1. Materials 
All reagents for tissue culture were purchased from Life Technolo- 
gies, Paisley, Strathclyde, UK. [3H]Dihydroalprenolol (56 Ci/mmole), 
@*P]ATP and [3H]cAMP were obtained from Amersham Interna- 
tional. Betaxolol was a kind gift from Dr. V. Rovei, Synthelabo Re- 
cherche, Bagneux, France. Other B-adrenoceptor active compounds 
were purchased from the Sigma Chemical Company (Poole, UK) or 
from Research Biochemicals International (Natick, MA, USA). Ilo- 
prost was a kind gift of Schering Health Care, Burgess Hill, Sussex, 
UK. All other chemicals were bought from Sigma or British Drug 
Houses (BDH) and were of the highest purity available. The cDNAs 
for the human wild-type and CAMBs-adrenoceptors [5] were a gift 
from Dr. R.J. Lefkowitz (HHMI, Duke University, NC, USA). 
2.2. Methods 
2.2.1. Generation and isolation of ceil lines. Plasmid pJMl6 [8], 
which harbours a copy of the neomycin resistance gene, was cut 
with the restriction enzymes BamHI and XhoI to allow a cDNA en- 
coding the wild-type human Bs-adrenoceptor to be ligated down- 
stream of the B-actin promoter of this plasmid [9,10]. ‘Genecleaned’ 
(Life Technologies) wild-type human Bs-adrenoceptor cDNA, with 5’ 
BamHI and 3’ XhoI sites, was ligated into the digested pJMl6. For 
the CAMBs-adrenoceptor, the cDNA in vector pRK5 was co-trans- 
fected with the neomycin-resist nce plasmid, pSV-neo. 10 pg of these 
DNAs was transfected into NGl08-15 cells using Lipofectin reagent 
(Life Technologies) according to the manufacturer’s instructions. 
Clones that were resistant to geneticin sulphate (800 &ml) were 
selected and expanded. Expression of the Bz-adrenoceptor in mem- 
branes from these clones was assessed by the specific binding of the B- 
adrenoceptor antagonist $H]dihydroalprenolol (see below). 
2.2.2. Membrane prepa~at&n. _ Membrane fractions were prepared 
from cell pastes which had been stored at -80°C following harvest 
essentially as described [l 11. Frozen cell pellets were suspended in 5 ml 
10 mM TrislHCl, 0.1 mM EDTA, pH 7.5 (TE buffer) and rupture of 
the cells achieved with 25 strokes of a hand-held Teflon on glass 
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homogeniser. The resulting homogenate was centrifuged at 500 X g for 
10 min in a Beckman L5-50B centrifuge with a Ti50 rotor to remove 
unbroken cells and nuclei. The supernatant fraction from this treat- 
ment was then centrifuged at 48 000 X g for 10 min and the pellet from 
this treatment washed and resuspended in 10 ml TE buffer. Following 
a second centrifugation at 48 000 Xg for 10 min the membrane pellet 
was resuspended in TE buffer to a final protein concentration of l-3 
mg/ml and stored at -80°C until required. 
2.2.3. Adenylyl cyclase activity assays. These were performed as 
described by Milligan et al. [12]. Each assay contained 100 mM 
Tris-HCl, pH 7.5, 20 mM creatine phosphate, 50 mM NaCI, 5 mM 
MgC12, 1 mM CAMP, 1 FM GTP, 10 U creatine phosphokinase and 
0.2 mM ATP containing 1 @i a[32P]ATP. Separation of radiolabelled 
CAMP and ATP was achieved using the double column method de- 
scribed by Johnson and Salomon [13]. 
2.2.4. fHJDihydroalprenolo1 binding assays. In routine experi- 
ments a single concentration (2 nM) of [3H]dihydroalprenolol 
([3H]DHA) in the absence and presence of 10 pM propranolol was 
used to define total and non-specific binding respectively. Assays were 
performed at 37°C for 30 min in 20 mM Tris-HCl (pH 7.5), 50 mM 
sucrose, 20 mM MgClz (TSM buffer). All binding experiments were 
terminated by rapid filtration through Whatman GF/C filters followed 
by three washes (5 ml) with ice-cold TSM buffer. 
2.2.5. Western analysis. Membrane proteins were resolved by 
SDS-PAGE (10% (w/v) acrylamide) and subsequently transferred to 
nitrocellulose for immunoblotting. For detection of G,a, antiserum 
CS was used. For detection of G,alGlla, antiserum CQ was used. 
These antisera [14,15] were raised in New Zealand White rabbits after 
immunization with a glutaraldehyde conjugate of keyhole limpet hae- 
mocyanin and the synthetic peptides, RMHLRQYELL and 
QLNLKEYNLV, which correspond to the C-terminal decapeptide 
regions of the G,CL isoforms and Gqcx/G1l~ respectively. 
3. Results 
The specific binding of [3H]dihydroalprenolo1 ([3H]DHA) 
(2 x 10Pg M) to membranes of clone 22 which stably expresses 
the CAMBz-adrenoceptor was competed for by varying con- 
centrations of the P-adrenoceptor ligands sotalol, betaxolol, 
timolol, dihydroalprenolol and propranolol. Betaxolol and 
sotalol were substantially less potent than the other com- 
pounds tested (Fig. 1). PH]DHA had a measured Kd of 
8.8 f 3.9 x lo-lo M at this receptor (data not shown) allowing 
the following estimates for Ki : propranolol 3.0 f 0.6 X lo-’ M, 
dihydroalprenolol 1.6 k 0.4X lo-’ M, timolol 2.5 f 0.8 X lo-’ 
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Fig. 1. Competition between [3H]dihydroalprenolo1 and various p- 
receptor ligands for the CAMPz-adrenoceptor. Membranes prepared 
from clone 22 cells were incubated with [3H]DHA (2X 10eg M) and 
varying concentrations of propranolol, dihydroalprenolol, timolol, 
sotalol or betaxolol and the specific binding of the radioligand as- 
sessed as described in Section 2.2. The results represent the means 
+_ S.E.M., from three independent experiments. 
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Fig. 2. Sotalol and betaxolol act as inverse agonists at the CAM& 
adrenoceptor and cause up-regulation of this receptor. A: Basal 
adenylyl cyclase activity and its regulation by varying concentrations 
of P-adrenoceptor ligands was measured in membranes of CAMPx- 
adrenoceptor expressing clone 22 cells. The data represent the 
means+ S.E.M., n=3. B: Clone 22 cells in culture were treated with 
or without a range of concentrations of a number of P-adrenoceptor 
ligands for 24 h. Membranes were subsequently prepared and the 
specific binding of [3H]DHA measured. 100% specifc [3H]DHA 
binding was equivalent to 790f 100 fmole/mg membrane protein. 
The data represent the means f S.E.M., n = 3. 
M, betaxolol 7.6 f 2.4~ lop7 M and sotalol 3.5 f 0.9 x lo-” M 
(all mean f S.E.M., n = 3). 
Membranes prepared from cells of clone 22 displayed high 
adenylyl cyclase activity in the absence of ligands in compar- 
ison to untransfected NGlO%15 cells or NG108-15 cells trans- 
fected to express varying levels of the wild-type Pz-adrenocep- 
tor (see Fig. 2A and [10,16] for examples). This basal adenylyl 
cyclase activity was inhibited in a concentration-dependent 
manner by both betaxolol (EC50 = 5.2 x lop7 M) and sotalol 
(EC50 = 3.5X lop6 M) (Fig. 2A), a response anticipated for 
inverse agonist ligands, whereas propranolol, timolol and di- 
hydroalprenolol had no significant effects (Fig. 2A). 
Addition and maintenance of varying concentrations of be- 
taxolol or sotalol to cultures of clone 22 for 24 h prior to cell 
harvest resulted in a substantial, concentration-dependent, in- 
crease (some 4-fold in response to betaxolol (1 x 10e5 M) and 
greater than 3-fold in response to sotalol (1 x 10d5 M)) in 
membrane levels of the CAMPz-adrenoceptor (from a basal 
level of 790 + 110 fmole/mg membrane protein) as measured 
by the specific binding of t3H]DHA (Fig. 2B), correlating with 
the inverse agonism of these ligands noted above (Fig. 2A). 
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Fig. 3. Inverse agonist up-regulation of the CAMPz-adrenoceptor 
requires receptor occupancy but not alterations in cellular CAMP le- 
vels. A: Cells of clone 22 were treated for 24 h with either sotalol 
or betaxolol (1 X 10m5 M) or with either of these agents in combina- 
tion with either propranolol or dihydroalprenolol (1 X 10m5 M) as 
indicated. Membranes were subsequently prepared and the specific 
binding of [3H]DHA measured. The data represent the means k S.D. 
of triplicate determinations. Similar data were produced in two in- 
dependent experiments. B: Cells of clone 22 were treated for 24 h 
with either vehicle, sotalol or betaxolol (1 X lO-5 M) or with the 
agents dibutyryl CAMP (1 X10m3 M) or SQ 22536 (1~10~~ M) 
added in parallel. The data represent the means + S.D. of triplicate 
determinations. Similar data were produced in two independent ex- 
periments. 
No significant alterations in levels of specific [3H]DHA bind- 
ing were observed following equivalent treatments with up to 
1 x lop5 M propranolol, timolol or dihydroalprenolol (Fig. 
2B). Importantly for the contention that up-regulation of 
the CAMj3z-adrenoceptor induced by betaxolol and sotalol 
was directly attributable to their interactions with the receptor 
and their function as inverse agonists, co-incubation of clone 
22 cells with either betaxolol or sotalol (1 x lop5 M) with 
either propranolol or dihydroalprenolol (1 X 10e5 M) for 24 
h prevented the up-regulatory effects of both inverse agonist 
ligands (Fig. 3A). 
As expression of the CAMPz-adrenoceptor results in ago- 
nist-independent stimulation of adenylyl cyclase which is in- 
hibited by the inverse agonists (see above) we examined 
whether the receptor up-regulation induced by betaxolol and 
sotalol would be prevented by maintained elevation of CAMP 
levels or mimicked by sustained inhibition of adenylyl cyclase. 
Addition of the cell-permeable second messenger analogue, 
dibutyryl CAMP (1 X lop3 M) for 24 h neither altered basal 
steady-state levels of the CAMPz-adrenoceptor or prevented 
the ability of either betaxolol or sotalol to cause up-regulation 
of the receptor (Fig. 3B). Furthermore, co-incubation with the 
adenylyl cyclase P-site inhibitor [17,18], SQ 22536 (1 X low4 
M), which acts to inhibit adenylyl cyclase activity (basal ade- 
nylyl cyclase activity in membranes of clone 22 cells in this set 
of experiments was 91.8 f 6.4 pmole/min/mg protein and in 
the presence of SQ 22536 it was 27.1 f 1.2 pmole/min/mg pro- 
tein (mean + S.D. of quadruplicate determinations)), was also 
without effect on either basal levels of the receptor or its up- 
regulation by betaxolol and sotalol (Fig. 3B). 
Sustained (24 h) treatment of NGl08-15 cells transfected to 
express the wild-type human Pz-adrenoceptor receptor (clone 
PN22) with isoprenaline resulted in a reduction in membrane- 
A 
Wild - type 
control llopmst i!4qmaK sotalol bstaxolol 
ligand 
Fig. 4. Inverse agonists fail to regulate cellular G protein levels de- 
spite regulation of receptor levels. A: Cells of clone PN22 (expres- 
sing the wild-type Pz-adrenoceptor) or clone 22 (expressing the 
CAMPz-adrenoceptor) were maintained for 24 h in the presence of 
vehicle (C), or 1 X 10m5 M of the IP prostanoid receptor agonist ilo- 
prost (I), isoprenaline (2), sotalol (3) or betaxolol (4). Membranes 
were subsequently prepared from these cells and following resolu- 
tion by SDS-PAGE the samples were immunoblotted with a combi- 
nation of antiserum CS (to detect G,a) and CQ (to detect G,a and 
Glla). Similar data were produced in two further independent ex- 
periments. B: The membranes produced in A had their specific 
[3H]DHA binding capacity determined. The data represent the 
means k S.D. of quadruplicate determinations. Similar data were 
produced in two further independent experiments. 
D.J. MacEwan, G. MilliganIFEBS Letters 399 (1996) 108-112 111 
associated levels of the a subunit of the G protein G,, which 
interacts with this receptor, as we have previously reported [9]. 
This was also true following sustained occupancy of the en- 
dogenously expressed (G,a-linked) IP prostanoid receptor 
with the agonist iloprost (Fig. 4). In contrast to this, sustained 
treatment with either of the inverse agonists betaxolol or so- 
talol failed to cause any detectable alteration in levels of this 
G protein (Fig. 4). Similar steady-state levels of Gsa were 
present in membranes of the CAMB2-expressing clone 22 cells 
as in those expressing the wild-type receptor. Equivalent 
down-regulation of G,a was observed in response to isoprena- 
line and iloprost in the CAMBz-adrenoceptor expressing clone 
22 (Fig. 4). Again, despite the strong up-regulation of the 
receptor in response to sotalol and betaxolol, no up-regulation 
of G,a could be detected in parallel (Fig. 4). As a control in 
these experiments relative levels of the phosphoinositidase C- 
linked G proteins were also measured in the same assays. No 
alteration in levels of G,aIGiia G proteins were observed 
associated with any of the treatments employed (Fig. 4). 
4. Discussion 
Inverse agonists are expected to stabilise inactive conforma- 
tions of GPCRs. Thus, they should reduce the basal input into 
signalling cascades produced by agonist-unoccupied GPCRs 
as this is thought to reflect the equilibrium position between 
inactive and active receptor conformations [l-3]. As such, 
mutations in GPCRs which show greater agonist-independent 
signalling than the wild-type receptors would be expected to 
provide easier model systems with which to examine the char- 
acteristics of inverse agonist ligands. 
The current study demonstrates that sustained treatment of 
cells expressing a CAM human Pz-adrenoceptor with inverse 
agonist ligands can produce a marked upregulation of this 
receptor. A key feature of the action of an agonist ligand 
(whether positive or inverse) is that its effects should be pre- 
vented by the presence of an antagonist ligand. Although it is 
standard to demonstrate this for positive agonists it is a sim- 
ple pharmacological test often overlooked in studies on po- 
tential inverse agonist ligands. As such, an important feature 
of these studies was the demonstration that betaxolol and 
sotalol-induced CAMBz-adrenoceptor up-regulation was 
blocked by co-incubation with either propranolol or dihy- 
droalprenolol (Fig. 3A) even though these compounds alone 
had no significant effects on receptor levels (Fig. 2). The neu- 
tral antagonists used in this study display substantially greater 
affinity (at least loo-fold) to bind to the CAM Pe-adrenocep- 
tor than the inverse agonists and thus it was a simple process 
to allow equimolar concentrations of the antagonists to com- 
pete with the inverse agonists for binding to the receptor. 
Such studies also help to define that the effects of betaxolol 
and sotalol require their interaction with the receptor and are 
not a reflection of some non-specific and trivial interaction 
with the cells. It is also of interest in this regard that the 
estimated Ki values for betaxolol and sotalol in this system 
were in close agreement with the measured ECso values for 
inhibition of basal adenylyl cyclase activity but that the meas- 
ured EC50 values for CAM Bs-adrenoceptor upregulation 
were some 3-5-fold lower (see Section 3). As noted above, 
both betaxolol and sotalol have relatively low affinity at the 
CAMBz-adrenoceptor whereas the high affinity ligands exam- 
ined in this study were not inverse agonists. Further studies 
will be required to examine if this is significant, but one pos- 
sibility derived from this observation is that the binding site 
for inverse agonists is not identical to that for antagonist 
ligands. This should not be considered too unlikely as in the 
catecholamine receptors sites of greater or lesser importance 
for the binding of agonist and antagonist ligands have been 
identified [19,20] and agonist ligands tend to have lower affin- 
ity at receptors than antagonists as their role involves selec- 
tion between different receptor conformations and their stabi- 
lisation. 
The demonstration that two B-blockers, sotalol and betax- 
0101, have the capacity to inhibit basal adenylyl cyclase activ- 
ity in membranes of cells derived from neuroblastoma X glio- 
ma hybrid, NG108-15, cells following their transfection and 
stable expression of a CAM human Pa-adrenoceptor defines 
these compounds as inverse agonists at this receptor. It was 
thus of considerable interest to note that sustained (24 h) 
exposure of cells expressing the CAMPa-adrenoceptor to 
both betaxolol and sotalol resulted in a substantial up-regula- 
tion of levels of the receptor as subsequently measured by the 
binding of TH]DHA. The ability of a single concentration of 
betaxolol to cause up-regulation of the CAMBz-adrenoceptor 
has previously been noted in CHO cells [21]. However, as used 
in this report, the NG10815 cell background provides more 
marked and reproducible inverse agonism responses than in 
other cell lines we have examined expressing the same 
CAMPa-adrenoceptor construct, including CHO cells (D.J. 
MacEwan and G. Milligan, unpublished observations). 
As cells expressing the CAMBz-adrenoceptor show elevated 
agonist-independent adenylyl cyclase activity, and thus gen- 
eration of CAMP, we wished to ascertain whether inhibition 
of adenylyl cyclase and reduction in CAMP levels by a distinct 
mechanism would mimic the effect of the inverse agonists in 
inducing receptor up-regulation. To do so, we took advantage 
of the ability of a so-called adenylyl cyclase ‘P-site’ inhibitor 
[17,18] to block the generation of CAMP. Treatment of the 
CAMPa-adrenoceptor expressing cells with SQ 22536 had no 
significant effect on either steady-state levels of the receptor or 
on the ability of sotalol or betaxolol to increase these levels 
(Fig. 3B), although it reduced substantially the basal adenylyl 
cyclase activity in membranes of these cells. Furthermore, as 
treatment with the cell permeant and phosphodiesterase resist- 
ant analogue of CAMP, dibutyryl CAMP, was unable to pre- 
vent the effect of the inverse agonists we can eliminate a key 
role of the agonist-independent stimulation of adenylyl cyclase 
in these cells in the process of receptor up-regulation. 
We have previously noted in a range of systems that sus- 
tained agonist occupancy of a GPCR can result in a selective 
down-regulation of the G protein a-subunit coupled to that 
receptor (as long as levels of receptor expression are suffi- 
ciently high such that a significant fraction of the relevant 
G protein a-subunit pool is activated) (see [22] for review). 
We confirmed that this phenomenon could be observed in the 
CAMBz-adrenoceptor expressing NG108-15 cells via both this 
receptor (in response to isoprenaline) and via an endogenously 
expressed IP prostanoid receptor (Fig. 4) and then further 
examined whether sustained occupancy of the CAMBZ-adre- 
noceptor with inverse agonists might conversely result in an 
up-regulation of G protein levels. We were unable to record 
such an effect despite there being marked up-regulation of the 
CAMPz-adrenoceptor in the same preparations (Fig. 4). Thus, 
although down-regulation of both receptor and G-protein can 
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occur in response to positive agonists, the converse was not 
true of inverse agonists which resulted in up-regulation of 
receptor levels only. Although agonist-induced down-regula- 
tion of G proteins often occurs in the same temporal frame- 
work as down-regulation of the GPCR, these two processes 
were recently shown to be independent [23,24]. As such, it 
might be rather naive to anticipate that there would be 
coupled regulation of the levels of expression of different ele- 
ments of a signalling cascade which would be dependent upon 
the conformational status of just the receptor. 
The current studies provide evidence from a novel strategy, 
based on the up-regulation of 3H ligand binding sites, that 
betaxalol and sotalol act as inverse agonists at the CAMPz- 
adrenoceptor and importantly demonstrate that this effect can 
be produced in a whole cell. A criticism of certain studies on 
inverse agonism has been that it is easier to observe responses 
consistent with such a pharmacology in assays which utilise 
broken cell preparations rather than whole cell systems. 
A recent report has demonstrated a similar phenomenon to 
that reported herein for the histamine Hz receptor [25]. Sus- 
tained treatment of CHO cells transfected to express this re- 
ceptor with compounds such as cimetidine or ranitidine, 
which were shown to have inverse agonists properties, caused 
an upregulation of the receptor whereas equivalent treatment 
with burimamide, which acted as a neutral antagonist, was 
unable to replicate this effect [25]. Although the effects in 
the studies of Smits et al. [25] were relatively small compared 
to the degree of upregulation reported herein, they examined 
the wild-type rather than a mutationally modified form of 
histamine Hz receptor. We have also noted that betaxolol 
treatment produces up-regulation of the wild-type human 
Pz-adrenoceptor [26] (Fig. 4B), although the effect is much 
smaller than when using the CAM version of the receptor. 
The mechanisms responsible for the upregulation does not 
seem to involve alteration in receptor mRNA but does require 
de novo protein synthesis [26] and it may be that the inverse 
agonists cause a stabilization of the receptor structure which 
would result in a decreased rate of turnover. This hypothesis, 
however, awaits direct examination. 
It will be of interest to discover if these findings represent a 
general feature of inverse agonists compared to antagonists 
drugs at a wide range of GPCRs. A considerable number of 
activating mutations have now been recorded for a wide range 
of receptor types and as such these questions are amenable to 
direct examination [5-7,27,28]. 
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